Loading, Please Wait...
TORONTO, ON --(Marketwired - February 12, 2016) -
NOT FOR DISSEMINATION IN THE UNITED STATES OF AMERICA OR THROUGH U.S. NEWSWIRE SERVICE
Beleave Inc. (the "Corporation" or "Beleave") (CSE: BE) wishes to announce that it has entered into a debt settlement agreement with a consultant whereby Beleave will settle up to $40,000 of outstanding payables through the issuance of 100,000 common shares at a deemed price of $0.40 per common share. All securities issued in the debt settlement are subject to a statutory hold period expiring four months and one day after the issuance of common shares.
The Corporation is also pleased to announce that it has entered into a consulting agreement (the "Consulting Agreement") for capital market advisory services including but not limited to financing, corporate communications and business development. Pursuant to the Consulting Agreement, the Corporation may issue common shares in lieu of cash for services provided, and has elected to satisfy its payment obligations for the first month of services provided through the issuance of 26,250 common shares at a deemed price of $0.40 per common share.
All share issuances are subject to applicable regulatory (including the Canadian Securities Exchange) approvals.
Beleave Inc. (formerly Stream Ventures Inc.) is a biotech company committed to becoming a licensed producer under the Marihuana for Medical Purposes Regulations (the "MMPR"). Beleave's wholly-owned subsidiary First Access Medical Inc. ("FAM") has applied for a licence to cultivate and sell medical marihuana pursuant to the MMPR. As of the date hereof, FAM has successfully advanced past the security clearance stage and is currently in the review stage of the licensing process. Beleave's purpose built facility is located near Hamilton, Ontario.
For more information contact:
Sebastian de Kloet
Phone: 1 (905) 979 - 5173